Publications

12 items matching your search terms.

MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer

Portman, N.; Chen, J.; Lim, E.

Frontiers in Oncology 11 :777867, 2021 10.3389/fonc.2021.777867

DNA methylation is required to maintain both DNA replication timing precision and 3D genome organization integrity

Du, Q.; Smith, G. C.; Luu, P. L.; Ferguson, J. M.; Armstrong, N. J.; Caldon, C. E.; Campbell, E. M.; Nair, S. S.; Zotenko, E.; Gould, C. M.; Buckley, M.; Chia, K. M.; Portman, N.; Lim, E.; Kaczorowski, D.; Chan, C. L.; Barton, K.; Deveson, I. W.; Smith, M. A.; Powell, J. E.; Skvortsova, K.; Stirzaker, C.; Achinger-Kawecka, J.; Clark, S. J.

Cell Reports 36 (12) :109722, 2021 10.1016/j.celrep.2021.109722

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

Alves, C. L.; Ehmsen, S.; Terp, M. G.; Portman, N.; Tuttolomondo, M.; Gammelgaard, O. L.; Hundebol, M. F.; Kaminska, K.; Johansen, L. E.; Bak, M.; Honeth, G.; Bosch, A.; Lim, E.; Ditzel, H. J.

Nature Communications 12 (1) :5112, 2021 10.1038/s41467-021-25422-9

Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition

Aziz, D.; Portman, N.; Fernandez, K. J.; Lee, C.; Alexandrou, S.; Llop-Guevara, A.; Phan, Z.; Yong, A.; Wilkinson, A.; Sergio, C. M.; Ferraro, D.; Etemadmoghadam, D.; Bowtell, D. D.; kConFab, Investigators; Serra, V.; Waring, P.; Lim, E.; Caldon, C. E.

NPJ Breast Cancer 7 (1) :111, 2021 10.1038/s41523-021-00312-x

Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer

Freelander, A.; Brown, L. J.; Parker, A.; Segara, D.; Portman, N.; Lau, B.; Lim, E.

Genes 12 (2) 2021 10.3390/genes12020285

Estrogen receptor positive breast cancer patient derived xenograft models in translational research.

Chia, K.; Freelander, A.; Kumar, S.; Parker, A.; Segara, D.; Portman, N.; Lim, E.

Current Opinion in Endocrine and Metabolic Research 15 :31-36, 2020

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer

Portman, N.; Milioli, H. H.; Alexandrou, S.; Coulson, R.; Yong, A.; Fernandez, K. J.; Chia, K. M.; Halilovic, E.; Segara, D.; Parker, A.; Haupt, S.; Haupt, Y.; Tilley, W. D.; Swarbrick, A.; Caldon, C. E.; Lim, E.

BREAST CANCER RESEARCH 22 (1) :87, 2020 10.1186/s13058-020-01318-2

Targeting CDK2 in cancer: challenges and opportunities for therapy

Tadesse, S.; Anshabo, A. T.; Portman, N.; Lim, E.; Tilley, W.; Caldon, C. E.; Wang, S.

DRUG DISCOVERY TODAY 25 (2) :406-413, 2020 10.1016/j.drudis.2019.12.001

Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer

Kennedy, S. P.; Han, J. Z. R.; Portman, N.; Nobis, M.; Hastings, J. F.; Murphy, K. J.; Latham, S. L.; Cadell, A. L.; Miladinovic, D.; Marriott, G. R.; O'Donnell, Y. E. I.; Shearer, R. F.; Williams, J. T.; Munoz, A. G.; Cox, T. R.; Watkins, D. N.; Saunders, D. N.; Timpson, P.; Lim, E.; Kolch, W.; Croucher, D. R.

BREAST CANCER RESEARCH 21 (1) :43, 2019 10.1186/s13058-019-1127-y

Overcoming CDK4/6 inhibitor resistance in ER positive breast cancer

Portman, N.; Alexandrou, S.; Carson, E.; Wang, S.; Lim, E.; Caldon, C. E.

ENDOCRINE-RELATED CANCER 26 :R15-R30, 2019 10.1530/erc-18-0317

Non-canonical AR activity facilitates endocrine resistance in breast cancer

Chia, K.; Milioli, H.; Portman, N.; Laven-Law, G.; Coulson, R.; Yong, A.; Segara, D.; Parker, A.; Caldon, C. E.; Deng, N.; Swarbrick, A.; Tilley, W. D.; Hickey, T. E.; Lim, E.

ENDOCRINE-RELATED CANCER 26 (2) :251-264, 2019 10.1530/erc-18-0333

Pushing estrogen receptor around in breast cancer

Lim, E.; Tarulli, G.; Portman, N.; Hickey, T.; Tilley, W. D.; Palmieri, C.;

ENDOCRINE-RELATED CANCER 2016